Ramucirumab (anti-VEGFR)
Based on 1 publication(s) in Google Scholar
Ramucirumab (anti-VEGFR) is a human VEGFR-2 antagonist for the treatment of solid tumors. Ramucirumab (anti-VEGFR) is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D. Ramucirumab (anti-VEGFR) is also an angiogenesis inhibitor.
For research use only. We do not sell to patients.
- Purity: 99.9%
- CAS No.: 947687-13-0
- Molecular Weight:144.56 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Ramucirumab (anti-VEGFR)
MoreAll VEGFR Isoforms
More
Biological Activity
Human IgG1 kappa
Human
KDR
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
-
Immobilized Human VEGFR2/KDR/CD309, Fc Tag can bind Ramucirumab (anti-VEGFR). The EC50for this effect is 16.83 ng/mL.
Chemical Information
-
CAS No. 947687-13-0
-
Appearance Liquid
-
Molecular Weight 144.56 kDa
-
Color Colorless to light yellow
-
SMILES
[Ramucirumab (anti-VEGFR)]
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
Purity & Documentation
-
Data Sheet (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Fala L. Cyramza (Ramucirumab) Approved for the Treatment of Advanced Gastric Cancer and Metastatic Non-Small-Cell Lung Cancer. Am Health Drug Benefits. 2015 Mar;8(Spec Feature):49-53. [Content Brief]
[2]. Oholendt AL, et al. Ramucirumab: A New Therapy for Advanced Gastric Cancer. J Adv Pract Oncol. 2015 Jan-Feb;6(1):71-5. [Content Brief]
[3]. Lowery CD, et al. Anti-VEGFR2 therapy delays growth of preclinical pediatric tumor models and enhances anti-tumor activity of chemotherapy. Oncotarget. 2019 Sep 17;10(53):5523-5533. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)